Bruker (BRKR) | Financial Analysis & Statements
Bruker Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
977.2M
Gross Profit
449.2M
45.97%
Operating Income
111.8M
11.44%
Net Income
29.2M
2.99%
EPS (Diluted)
$0.10
Balance Sheet Metrics
Total Assets
6.2B
Total Liabilities
3.7B
Shareholders Equity
2.5B
Debt to Equity
1.49
Cash Flow Metrics
Operating Cash Flow
108.7M
Free Cash Flow
177.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Bruker Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.4B | 3.4B | 3.0B | 2.5B | 2.4B |
| Cost of Goods Sold | 1.9B | 1.7B | 1.5B | 1.2B | 1.2B |
| Gross Profit | 1.6B | 1.6B | 1.5B | 1.3B | 1.2B |
| Gross Margin % | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% |
| Operating Expenses | |||||
| Research & Development | 395.2M | 376.5M | 294.8M | 235.9M | 220.8M |
| Selling, General & Administrative | 946.5M | 893.8M | 730.1M | 610.8M | 564.5M |
| Other Operating Expenses | - | - | 5.0M | 3.0M | 2.8M |
| Total Operating Expenses | 1.3B | 1.3B | 1.0B | 849.7M | 788.1M |
| Operating Income | 236.0M | 379.2M | 488.4M | 459.0M | 424.3M |
| Operating Margin % | 6.9% | 11.3% | 16.5% | 18.1% | 17.5% |
| Non-Operating Items | |||||
| Interest Income | 14.8M | 9.3M | 11.2M | 4.1M | 900.0K |
| Interest Expense | 60.3M | 47.9M | 16.4M | 16.1M | 14.3M |
| Other Non-Operating Income | -167.3M | -133.7M | 61.0M | -33.1M | -17.3M |
| Pre-tax Income | 22.0M | 206.9M | 544.2M | 413.9M | 393.6M |
| Income Tax | 29.3M | 91.4M | 117.7M | 116.4M | 113.0M |
| Effective Tax Rate % | 133.2% | 44.2% | 21.6% | 28.1% | 28.7% |
| Net Income | -8.3M | 113.8M | 428.5M | 298.5M | 280.6M |
| Net Margin % | -0.2% | 3.4% | 14.5% | 11.8% | 11.6% |
| Key Metrics | |||||
| EBITDA | 456.8M | 562.6M | 604.2M | 548.1M | 511.5M |
| EPS (Basic) | $-0.15 | $0.76 | $2.92 | $2.00 | $1.83 |
| EPS (Diluted) | $-0.15 | $0.76 | $2.90 | $1.99 | $1.81 |
| Basic Shares Outstanding | 151800000 | 149000000 | 146400000 | 148600000 | 151400000 |
| Diluted Shares Outstanding | 151800000 | 149000000 | 146400000 | 148600000 | 151400000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Bruker Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 298.8M | 183.4M | 488.3M | 645.5M | 1.1B |
| Short-term Investments | - | - | - | 0 | 100.0M |
| Accounts Receivable | 544.9M | 565.5M | 492.0M | 472.7M | 416.9M |
| Inventory | 1.1B | 1.1B | 968.3M | 800.1M | 710.1M |
| Other Current Assets | 24.1M | 28.9M | 18.3M | 12.8M | 172.2M |
| Total Current Assets | 2.2B | 2.1B | 2.2B | 2.1B | 2.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 165.8M | 145.5M | 91.7M | 51.2M | 59.9M |
| Goodwill | 4.0B | 3.9B | 1.5B | 1.2B | 890.8M |
| Intangible Assets | 899.6M | 912.5M | 330.5M | 270.9M | 211.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 671.0M | 518.9M | 481.2M | 231.9M | 160.9M |
| Total Non-Current Assets | 4.0B | 3.8B | 2.1B | 1.5B | 1.2B |
| Total Assets | 6.2B | 5.8B | 4.2B | 3.6B | 3.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 215.9M | 234.1M | 202.7M | 178.4M | 147.4M |
| Short-term Debt | 51.8M | 64.6M | 144.5M | 35.1M | 130.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 165.1M | 112.5M | 34.7M | 9.6M | 11.6M |
| Total Current Liabilities | 1.3B | 1.3B | 1.2B | 914.3M | 938.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.0B | 2.2B | 1.2B | 1.2B | 1.3B |
| Deferred Tax Liabilities | 112.5M | 118.5M | 67.7M | 62.3M | 46.0M |
| Other Non-Current Liabilities | 239.2M | 311.0M | 163.6M | 120.8M | 162.2M |
| Total Non-Current Liabilities | 2.5B | 2.7B | 1.6B | 1.6B | 1.6B |
| Total Liabilities | 3.7B | 4.0B | 2.8B | 2.5B | 2.6B |
| Equity | |||||
| Common Stock | 1.8M | 1.8M | 1.7M | 1.7M | 1.7M |
| Retained Earnings | 2.4B | 2.4B | 2.3B | 1.9B | 1.7B |
| Treasury Stock | 1.2B | 1.2B | 1.2B | 1.1B | 820.3M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.5B | 1.8B | 1.4B | 1.1B | 1.1B |
| Key Metrics | |||||
| Total Debt | 2.0B | 2.2B | 1.4B | 1.3B | 1.4B |
| Working Capital | 933.3M | 771.9M | 962.1M | 1.2B | 1.5B |
Balance Sheet Composition
Bruker Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -8.3M | 113.8M | 428.5M | 298.5M | 280.6M |
| Depreciation & Amortization | 220.3M | 183.8M | 114.9M | 88.8M | 89.1M |
| Stock-Based Compensation | 20.2M | 25.3M | 24.0M | 27.7M | 17.2M |
| Working Capital Changes | -24.1M | -62.9M | -131.5M | -137.3M | -81.3M |
| Operating Cash Flow | 82.5M | 233.5M | 292.7M | 289.7M | 327.8M |
| Investing Activities | |||||
| Capital Expenditures | -90.8M | -114.2M | -95.8M | -115.3M | -87.1M |
| Acquisitions | -73.9M | -1.6B | -226.6M | -182.3M | -65.0M |
| Investment Purchases | -7.2M | -48.3M | -24.8M | -60.2M | -148.5M |
| Investment Sales | - | 4.8M | 21.2M | 106.2M | 108.2M |
| Investing Cash Flow | -167.1M | -1.8B | -326.0M | -251.6M | -192.4M |
| Financing Activities | |||||
| Share Repurchases | -10.0M | 0 | -152.3M | -263.1M | -153.3M |
| Dividends Paid | -32.9M | -30.2M | -29.4M | -29.8M | -24.2M |
| Debt Issuance | 754.0M | 2.2B | - | 300.0K | 490.5M |
| Debt Repayment | -1.2B | -1.3B | -21.5M | -111.0M | -800.0K |
| Financing Cash Flow | 135.1M | 1.2B | -193.4M | -415.3M | 318.7M |
| Free Cash Flow | 13.9M | 136.0M | 243.2M | 145.2M | 190.4M |
| Net Change in Cash | 50.5M | -300.0M | -226.7M | -377.2M | 454.1M |
Cash Flow Trend
Bruker Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
74.88
Forward P/E
15.01
Price to Book
2.24
Price to Sales
1.60
PEG Ratio
6.74
Profitability Ratios
Profit Margin
-0.25%
Operating Margin
6.58%
Return on Equity
-0.38%
Return on Assets
2.90%
Financial Health
Current Ratio
1.73
Debt to Equity
81.38
Beta
1.20
Per Share Data
EPS (TTM)
$-0.15
Book Value per Share
$16.15
Revenue per Share
$22.64
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BRKR | 5.6B | 74.88 | 2.24 | -0.38% | -0.25% | 81.38 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Masimo | 9.4B | 46.47 | 12.89 | 23.43% | -9.92% | 77.55 |
| Bio-Rad | 8.1B | 10.75 | 1.08 | 10.84% | 29.42% | 18.58 |
| Bio-Rad Laboratories | 7.6B | 10.98 | 1.11 | 10.84% | 29.42% | 18.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.






